{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05796167",
            "orgStudyIdInfo": {
                "id": "22-02-723-205"
            },
            "secondaryIdInfos": [
                {
                    "id": "1396075255",
                    "type": "OTHER",
                    "domain": "Acadia Pharmaceuticals Inc"
                }
            ],
            "organization": {
                "fullName": "State University of New York - Downstate Medical Center",
                "class": "OTHER"
            },
            "briefTitle": "Pimavanserin for Sleep in Parkinson Disease",
            "officialTitle": "Does Pimavanserin (Nuplazid) Improve Sleep in Patients With Parkinson Disease Psychosis? A Pilot Study",
            "therapeuticArea": [
                "Neurology"
            ],
            "study": "pimavanserin-for-sleep-in-parkinson-disease"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-04-04",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-09",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-09",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-01-31",
            "studyFirstSubmitQcDate": "2023-03-21",
            "studyFirstPostDateStruct": {
                "date": "2023-04-03",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-07",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-08",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "State University of New York - Downstate Medical Center",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "ACADIA Pharmaceuticals Inc.",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "This pilot, self-control study is for patients with Parkinson's Disease (PD) psychosis (e.g., visual hallucinations, delusions) and sleep problems.",
            "detailedDescription": "This is a feasibility study to determine whether pimavanserin improves sleep quality in patients with PD and visual hallucinations/delusions.\n\nPatients will complete a Screening Visit to assess eligibility to participate in the study.\n\nFor more information, please contact Sofya Glazman, a study coordinator, at sofya.glazman@downstate.edu"
        },
        "conditionsModule": {
            "conditions": [
                "Parkinson Disease"
            ],
            "keywords": [
                "sleep",
                "visual hallucinations",
                "delusions"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "EARLY_PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "self-control, pilot study",
                "primaryPurpose": "OTHER",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 10,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Pimavanserin (Nuplazid)",
                    "type": "EXPERIMENTAL",
                    "description": "Pimavanserin (Nuplazid) 34 mg oral capsules once a day for 6 weeks for patients with Parkinson disease psychosis (e.g., visual hallucinations, delusions) and sleep problems",
                    "interventionNames": [
                        "Drug: Pimavanserin"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Pimavanserin",
                    "description": "Pimavanserin (Nuplazid) 34 mg oral capsules once a day for 6 weeks",
                    "armGroupLabels": [
                        "Pimavanserin (Nuplazid)"
                    ],
                    "otherNames": [
                        "Nuplazid"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Effect of pimavanserin on sleep fragmentation",
                    "description": "Number of arousals and the arousal index (arousals per hour of sleep) measured on polysomnography",
                    "timeFrame": "6 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Effect of pimavanserin on REM (Rapid Eye Movements) sleep behavior disorder",
                    "description": "Presence fo REM sleep without atonia (RWA) on polysomnograophy",
                    "timeFrame": "6 weeks"
                },
                {
                    "measure": "Effect of pimavanserin on sleep latency",
                    "description": "Time to first epoch on polysomnography",
                    "timeFrame": "6 weeks"
                },
                {
                    "measure": "Effect of pimavanserin on total sleep time",
                    "description": "Total sleep time measured on polysomnography",
                    "timeFrame": "6 weeks"
                },
                {
                    "measure": "Effect of pimavanserin on sleep efficiency",
                    "description": "Sleep Efficiency Index in percent is the ratio of total sleep time (based on polysomnography recordings) to time in bed",
                    "timeFrame": "6 weeks"
                },
                {
                    "measure": "Effect of pimavanserin on time in each sleep stage",
                    "description": "Time in each sleep stage as measured on polysomnography",
                    "timeFrame": "6 weeks"
                },
                {
                    "measure": "Effect of pimavanserin on subjective measure of REM Sleep behavior disorder",
                    "description": "RBDSQ (REM (Rapid Eye Movements) Sleep Behavior Disorder Screening Questionnaire to assess the most prominent clinical features of RBD. It is a 10-item, patient self-rating instrument with short questions to be answered by either 'yes' or 'no'.",
                    "timeFrame": "6 weeks"
                },
                {
                    "measure": "Effect of pimavanserin on subjective measures of sleep",
                    "description": "PDSS-2 (Parkinson's Disease Sleep Scale Version 2) total score ranges from 0 (no disturbance) to 60 (maximum nocturnal disturbance). Scores \\> 18 are considered as relevant sleep disturbances",
                    "timeFrame": "6 weeks"
                },
                {
                    "measure": "Effect of pimavanserin on subjective measures of fatigue",
                    "description": "PFS-16 (Parkinson's disease Fatigue Scale): 16-item scale with the following scoring for each item: strong disagree -1, disagree - 2, neither agree or disagree - 3, agree - 4, strongly agree - 5; with overall score of \u22658 indicates the presence of significant fatigue.",
                    "timeFrame": "6 weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion criteria:\n\n1. Has a diagnosis of idiopathic PD according to UK (United Kingdom) PD Society Brain Bank diagnostic criteria\n2. Has a history of hallucinations or delusions associated with PD\n3. Has a history of sleep disturbance\n4. Is between the ages of 40 and 85\n5. Has been on a stable dose of all PD medications for at least 30 days prior to enrolment\n\nExclusion criteria\n\n1. Has evidence of an atypical or secondary parkinsonian disorder\n2. Has a contraindication to taking pimavanserin\n3. Has contraindication to PSG\n4. There has been a change to patient's neuropsychiatric medications including dopaminergic medications (Sinemet, dopamine agonists, MAO(monoamine oxidaze)-B inhibitors), SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin and Norepinephrine Reuptake Inhibitors), dopamine-blocking agents, anti-epileptics, anticholinergics, or benzodiazepines for at least 30 days prior to enrollment\n5. Has traveled through 3 or more time zones within 60 days prior to study screening\n6. Patient is a night-shift worker",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "40 Years",
            "maximumAge": "85 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Sofya Glazman",
                    "role": "CONTACT",
                    "phone": "7182702841",
                    "email": "sofya.glazman@downstate.edu"
                },
                {
                    "name": "Christian J Amlang, MD",
                    "role": "CONTACT",
                    "email": "christian.amlang@downstate.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Christian J Amlang, MD",
                    "affiliation": "State University of New York - Downstate Medical Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "SUNY Downstate Health Sciences University",
                    "status": "RECRUITING",
                    "city": "Brooklyn",
                    "state": "New York",
                    "zip": "11203",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Sofya Glazman",
                            "role": "CONTACT",
                            "phone": "718-270-2841",
                            "email": "sofya.glazman@downstate.edu"
                        },
                        {
                            "name": "Christian Amlang, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.6501,
                        "lon": -73.94958
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "documentSection": {
        "largeDocumentModule": {
            "largeDocs": [
                {
                    "typeAbbrev": "Prot",
                    "hasProtocol": true,
                    "hasSap": false,
                    "hasIcf": false,
                    "label": "Study Protocol",
                    "date": "2023-01-17",
                    "uploadDate": "2023-04-03T11:18",
                    "filename": "Prot_001.pdf",
                    "size": 708628
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000010300",
                    "term": "Parkinson Disease"
                }
            ],
            "ancestors": [
                {
                    "id": "D000020734",
                    "term": "Parkinsonian Disorders"
                },
                {
                    "id": "D000001480",
                    "term": "Basal Ganglia Diseases"
                },
                {
                    "id": "D000001927",
                    "term": "Brain Diseases"
                },
                {
                    "id": "D000002493",
                    "term": "Central Nervous System Diseases"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000009069",
                    "term": "Movement Disorders"
                },
                {
                    "id": "D000080874",
                    "term": "Synucleinopathies"
                },
                {
                    "id": "D000019636",
                    "term": "Neurodegenerative Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M13213",
                    "name": "Parkinson Disease",
                    "asFound": "Parkinson's Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M9304",
                    "name": "Hallucinations",
                    "relevance": "LOW"
                },
                {
                    "id": "M6902",
                    "name": "Delusions",
                    "relevance": "LOW"
                },
                {
                    "id": "M22494",
                    "name": "Parkinsonian Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M25603",
                    "name": "Ganglion Cysts",
                    "relevance": "LOW"
                },
                {
                    "id": "M16358",
                    "name": "Synovial Cyst",
                    "relevance": "LOW"
                },
                {
                    "id": "M4774",
                    "name": "Basal Ganglia Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5204",
                    "name": "Brain Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5742",
                    "name": "Central Nervous System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12029",
                    "name": "Movement Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M2217",
                    "name": "Synucleinopathies",
                    "relevance": "LOW"
                },
                {
                    "id": "M21558",
                    "name": "Neurodegenerative Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000510793",
                    "term": "Pimavanserin"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000978",
                    "term": "Antiparkinson Agents"
                },
                {
                    "id": "D000018726",
                    "term": "Anti-Dyskinesia Agents"
                },
                {
                    "id": "D000014150",
                    "term": "Antipsychotic Agents"
                },
                {
                    "id": "D000014149",
                    "term": "Tranquilizing Agents"
                },
                {
                    "id": "D000002492",
                    "term": "Central Nervous System Depressants"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000011619",
                    "term": "Psychotropic Drugs"
                },
                {
                    "id": "D000058830",
                    "term": "Serotonin 5-HT2 Receptor Antagonists"
                },
                {
                    "id": "D000012702",
                    "term": "Serotonin Antagonists"
                },
                {
                    "id": "D000018490",
                    "term": "Serotonin Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M263089",
                    "name": "Pimavanserin",
                    "asFound": "Lumpectomy",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4295",
                    "name": "Antiparkinson Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M16904",
                    "name": "Antipsychotic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M14474",
                    "name": "Psychotropic Drugs",
                    "relevance": "LOW"
                },
                {
                    "id": "M15512",
                    "name": "Serotonin",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "AnDyAg",
                    "name": "Anti-Dyskinesia Agents"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "PsychDr",
                    "name": "Psychotropic Drugs"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}